Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
This page aggregates 8 Q1 2026 earnings articles, from previews to transcripts and takeaways, to help you compare companies and plan investments.
40 articlesA biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Berkshire Hathaway sold stocks in Q1, exiting 16 positions as the conglomerate maintains a heavy concentration in sev...
As Target prepares for its Q1 2026 earnings call, savvy investors want clarity on sales growth, margins, and the path...
When a leading fund sells a sizable stake in a cyclical manufacturer after a rough quarter, investors want clarity. T...
Citi lowers Lucid's price target to $14 following a disappointing Q1 2026 and the withdrawal of 2026 guidance, while ...
Lulu's LVLU is shaping its 2026 earnings story through stronger direct channels, smarter pricing, and inventory disci...
Ondas (ONDS) reports its Q1 2026 results, revealing early signs of progress and persistent headwinds. This guide brea...
TriSalus investors are eyeing the Q1 2026 earnings update to gauge cash runway, pipeline progress, and milestone-driv...
This deep-dive breaks down senestech snes 2026 earnings for Q1, translating the numbers into practical signals for in...
This deep-dive breaks down accelerant (arx) 2026 earnings, translating the Q1 transcript into actionable takeaways. L...
Coca-Cola beat first-quarter 2026 expectations, raised guidance, and signaled margin improvement from an Africa dives...
Pangaea (PANL) 2026 earnings narrative hinges on revenue growth, margin expansion, and cash flow strength. This guide...